Inscobee and Apimeds Grant Irrevocable Proxy to APUS

On May 7, 2026, Inscobee Inc. and Apimeds Inc. filed Amendment No. 4 to their Schedule 13D regarding Apimeds Pharmaceuticals US, Inc. (APUS). The filing details a comprehensive Settlement Agreement, Side Letter, and Forbearance Agreement entered into on April 24, 2026, to resolve disputes related to a prior Merger Agreement. A key component of the settlement is the granting of an irrevocable proxy by the reporting persons to Dr. Vin Menon and Captain Sandeep Singh Yadav, allowing them to vote the shares on specific matters until at least July 30, 2026. Additionally, the reporting persons noted that their previous concerns regarding the existence of approximately 1,000 bitcoin held by the Issuer have been resolved following verification by independent PCAOB-registered accounting firms. While Inscobee Inc. maintains a 16.7% stake with 2,099,747 shares, the combined reporting group effectively manages a larger position, with Apimeds Inc. holding 4,316,618 shares (34.3%). The settlement also includes the dismissal of litigation and modifications to governance and standstill arrangements.